Loehe Florian, Schauer Rolf J
Department of Surgery, Ludwig-Maximilians-University of Munich, Klinikum Grosshadern, Munich, Germany.
Clin Rev Allergy Immunol. 2005 Apr;28(2):167-74. doi: 10.1385/CRIAI:28:2:167.
Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are progressive cholestatic liver diseases of supposed auto-immune etiology. The clinical course is unpredictable and, in many patients, leads to end-stage liver disease or a poor quality of life. Conservative therapy only has a limited effect on the natural history, but orthotopic liver transplantation(OLT) offers a definitive therapeutic option. Retrospective analysis was performed for 38 patients with PBC and 17 patients with PSC who underwent OLT between January 1986 and June 2003 at our institution. Median followup after OLT was 72 mo.Cumulative survival at 5 yr post-OLT was 84% in the PBC group and 73% in the PSC group. Compared with OLT for other benign diseases, actuarial survival rates at 5 and 10 yr post-OLT were significantly better for patients with PBC, whereas there was no difference in survival after OLT for patients with PSC. Survival rate at 5 yr post-OLT was significantly increased for patients with PBC who had a Child-Pugh B liver cirrhosis (93%) compared with those who had Child-Pugh C cirrhosis (60%). Retransplantation rate was 18.2% (resulting from biliary complications in three cases). Surgical techniques had no effect on outcome after OLT in both groups. We concluded that liver transplantation represents a safe and beneficial therapy for patients with end-stage PBC. Cirrhotic patients with PSC also benefit from OLT, with an outcome comparable to that of liver cirrhosis of other etiologies.
原发性胆汁性肝硬化(PBC)和原发性硬化性胆管炎(PSC)是推测为自身免疫病因的进行性胆汁淤积性肝病。临床病程不可预测,在许多患者中会导致终末期肝病或生活质量低下。保守治疗对自然病程的影响有限,但原位肝移植(OLT)提供了一种确定性的治疗选择。对1986年1月至2003年6月间在我院接受OLT的38例PBC患者和17例PSC患者进行了回顾性分析。OLT后的中位随访时间为72个月。PBC组OLT后5年的累积生存率为84%,PSC组为73%。与其他良性疾病的OLT相比,PBC患者OLT后5年和10年的精算生存率明显更好,而PSC患者OLT后的生存率没有差异。与Child-Pugh C级肝硬化的PBC患者(60%)相比,Child-Pugh B级肝硬化的PBC患者OLT后5年的生存率显著提高(93%)。再次移植率为18.2%(3例因胆道并发症)。手术技术对两组OLT后的结局均无影响。我们得出结论,肝移植对终末期PBC患者是一种安全有益的治疗方法。PSC肝硬化患者也从OLT中获益,其结局与其他病因的肝硬化相当。